Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Perfect JR, et al. Among authors: lutsar i. Clin Infect Dis. 2003 May 1;36(9):1122-31. doi: 10.1086/374557. Epub 2003 Apr 22. Clin Infect Dis. 2003. PMID: 12715306 Clinical Trial.
Safety of voriconazole and dose individualization.
Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND. Lutsar I, et al. Clin Infect Dis. 2003 Apr 15;36(8):1087-8. doi: 10.1086/374248. Clin Infect Dis. 2003. PMID: 12684928 No abstract available.
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N. Walsh TJ, et al. Among authors: lutsar i. Antimicrob Agents Chemother. 2004 Jun;48(6):2166-72. doi: 10.1128/AAC.48.6.2166-2172.2004. Antimicrob Agents Chemother. 2004. PMID: 15155217 Free PMC article. Clinical Trial.
Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure FX, Lortholary O; Voriconazole/Bone Invasive Aspergillosis Study Group. Mouas H, et al. Among authors: lutsar i. Clin Infect Dis. 2005 Apr 15;40(8):1141-7. doi: 10.1086/428734. Epub 2005 Mar 14. Clin Infect Dis. 2005. PMID: 15791514 Clinical Trial.
Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.
Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, Jafri H, Arrieta AC, Klein NJ, Lutsar I. Walsh TJ, et al. Among authors: lutsar i. Antimicrob Agents Chemother. 2010 Oct;54(10):4116-23. doi: 10.1128/AAC.00896-10. Epub 2010 Jul 26. Antimicrob Agents Chemother. 2010. PMID: 20660687 Free PMC article. Clinical Trial.
Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.
Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH, Lutsar I, Rovira M, Nguyen Q, Slavin M, Chen SC; Global Scedosporium Study Group. Troke P, et al. Among authors: lutsar i. Antimicrob Agents Chemother. 2008 May;52(5):1743-50. doi: 10.1128/AAC.01388-07. Epub 2008 Jan 22. Antimicrob Agents Chemother. 2008. PMID: 18212110 Free PMC article.
198 results